Quisinostat

Phase 2Small molecule

Johnson & Johnson

Quisinostat is one of 127 small molecule programs targeting Cutaneous T-cell lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

126

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cutaneous T-Cell LymphomaActive, not recruiting

Uveal MelanomaActive, not recruiting

GlioblastomaActive, not recruiting

Cutaneous T-Cell LymphomaPhase 2

Active, not recruiting

Uveal MelanomaPhase 2

Active, not recruiting

GlioblastomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

514 competitors in Glioblastoma

#DrugCompanyPhaseTrials

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

161 2

Ceenu

AAzurity Pharmaceuticals

Phase 3

22 3

Gleevec

Novartis

Phase 3

2 4

Cymbalta

Alnylam Pharmaceuticals

Phase 3

1 5

Scemblix

Novartis

Phase 3

1 6

Lexapro

AbbVie

Phase 3

1 7

Feraheme

AAzurity Pharmaceuticals

Phase 3

4 8

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

4 9

Zejula

GGlaxo Dba Glaxosmithkline

Phase 3

4 10

Droxia

TTheravia

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Active, not recruiting

Glioblastoma

NCT06824662

Q2 2030

Phase 2Recruiting

Uveal Melanoma

NCT06932757

Clinical

Trials by Indication[1]

Histone Deacetylase Inhibitor2 trials

Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy

Completed·NNewVac LLC·Phase 2·NCT02948075·31 enrolled

Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy

Completed·NNewVac LLC·Phase 1·NCT02728492·51 enrolled

Uveal Melanoma1 trial

Adjuvant Quisinostat in High-Risk Uveal Melanoma

Recruiting·UUniversity of Miami·Phase 2·NCT06932757·63 enrolled

Cutaneous T-cell lymphoma1 trial

A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT01486277·26 enrolled

Glioblastoma1 trial

Phase 0 With Expansion Phase Clinical Trial of Quisinostat Plus Radiotherapy in Newly-diagnosed and Recurrent Grade 4 IDH-Wildtype Glioblastomas

Active, not recruiting·NNader Sanai·Phase 1·NCT06824662·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Quisinostat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Quisinostat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Quisinostat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Johnson & Johnson

Quisinostat

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q2 2030

Trials by Indication[1]

Histone Deacetylase Inhibitor2 trials

Uveal Melanoma1 trial

Cutaneous T-cell lymphoma1 trial

Glioblastoma1 trial

References

Drug Info

Quick Facts

Related News